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The best-understood mechanisms for achieving antibody self/non-
self discrimination discard self-reactive antibodies before they can
be tested for binding microbial antigens, potentially creating holes
in the repertoire. Here we provide evidence for a complementary
mechanism: retaining autoantibodies in the repertoire displayed
as low levels of IgM and high IgD on anergic B cells, masking a
varying proportion of autoantibody-binding sites with carbohy-
drates, and removing their self-reactivity by somatic hypermuta-
tion and selection in germinal centers (GCs). Analysis of human
antibody sequences by deep sequencing of isotype-switched
memory B cells or in IgG antibodies elicited against allogeneic
RhD+ erythrocytes, vaccinia virus, rotavirus, or tetanus toxoid pro-
vides evidence for reactivation of anergic IgMlow IgD+ IGHV4-34+
B cells and removal of cold agglutinin self-reactivity by hyper-
mutation, often accompanied by mutations that inactivated an
N-linked glycosylation sequon in complementarity-determining re-
gion 2 (CDR2). In a Hy10 antibody transgenic model where anergic
B cells respond to a biophysically defined lysozyme epitope dis-
played on both foreign and self-antigens, cell transfers revealed
that anergic IgMlow IgD+ B cells form twice as many GC progeny
as naïve IgMhi IgD+ counterparts. Their GC progeny were rapidly
selected for CDR2 mutations that blocked 72% of antigen-binding
sites with N-linked glycan, decreased affinity 100-fold, and then
cleared the binding sites of blocking glycan. These results provide
evidence for a mechanism to acquire self/non-self discrimination
by somatic mutation away from self-reactivity, and reveal how
varying the efficiency of N-glycosylation provides a mechanism
to modulate antibody avidity.
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Following somatic recombination of Ig variable (V), diversity(D), and joining (J) gene elements, each B lymphocyte makes
a different antibody displayed on the plasma membrane as B-cell
antigen receptors (BCRs). Selection of antibodies to avoid binding
self-antigens is currently known to follow mechanisms conforming
to Burnet’s clonal selection hypothesis, whereby antibodies that
bind self are discarded during B-cell formation by receptor editing,
where the B cell undergoes a second Ig gene recombination, or by
clonal deletion of the B cell itself before the self-binding antibody
can be tested for binding to microbial antigens (1, 2). An alter-
native theoretical possibility raised by Jerne and by Diaz and
Klinman (3, 4) is that B cells bearing self-reactive antibodies
might somatically mutate away from self-reactivity, although this
possibility has not been experimentally addressed.
Approximately one-quarter of the preimmune B-cell reper-
toire display self-reactive antibodies on their cell surface pri-
marily containing a constant region segment of the IgD isotype,
with only a small proportion of their BCRs containing the IgM
constant region isotype. This IgD+ IgMlow subset has the pheno-
typic, biochemical, and functional characteristics of B cells that
have become anergic with intrinsically suppressed ability to
proliferate or secrete antibodies in response to most stimuli
(5–9). Here we investigate the possibility that display of
autoantibodies on IgD+ IgMlow anergic B cells allows somatic
mutation of the antibody away from self-reactivity, first by
studying the patterns of mutations in human antibodies using the
IGHV4-34 gene, and second by analyzing recurrent mutations in
the mouse Hy10 antibody against lysozyme that are selected when
anergic B cells are induced to form germinal centers by a foreign
antigen with the same lysozyme epitope as a self-antigen.
Results
Human IGHV4-34 Antibody Variants. In humans, antibodies using
the IGHV4-34*01 variable element are displayed as high IgD
and low IgM on 7% of circulating naïve B cells that are anergic
to BCR stimulation (10). IGHV4-34 antibodies are autoanti-
bodies that agglutinate self-erythrocytes at low temperatures
(cold agglutinins) by binding self-carbohydrate I/i antigens
composed of repeating N-acetyllactosamine units on the surface
of erythrocytes and B cells. This is due to an Ala–Val–Tyr
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hydrophobic patch in framework region 1 not present in other
IGHV4 family elements, is independent of complementarity-
determining region (CDR)3H or light-chain sequence, and is
abolished if the AVY residues are individually mutated (11–14)
(Fig. 1A). To extend earlier evidence that IGHV4-34+ IgD+
IgMlow anergic B cells are recruited into physiological germinal
center (GC) responses against foreign antigens (15), we per-
formed a Blastn search of the National Center for Biotechnology
Information (NCBI) nonredundant nucleotide database using
the IGHV4-34*01 sequence. The search revealed 14 human
antibodies with a hypermutated IGHV4-34*01 sequence that had
been elicited in normal individuals by repeated immunization
either with allogeneic RhD+ erythrocytes (16), rotavirus (17),
vaccinia virus (18), or tetanus toxoid (19) (Fig. 1A).
Four of the identified antibodies were RhD-specific aggluti-
nating IgM antibodies used in blood typing, and indeed the IgM
response to foreign RhD is dominated by IGHV4-34*01 anti-
bodies (16, 20). Three of the anti-RhD IgM antibodies retain the
AVY sequence and are known to retain self-reactivity measured
by agglutination of I/i antigen-bearing erythrocytes (20). Exper-
imentally introduced mutations in the AVY motif that inactivate
self-I/i agglutination also abolish RhD-mediated agglutination by
an IGHV4-34 IgM antibody (13), indicating that mutation away
from self-reactivity would come at the cost of losing foreign RhD
reactivity. Nevertheless, the AVY self-reactivity sequence has
been somatically mutated in one of the IgM anti-RhD antibodies
and in a high-affinity IgG anti-RhD antibody, Fog1, isolated
from the same donor as two of the IgM antibodies (FomA and
A
B
Fig. 1. Evidence for mutation away from self-reactivity in IGHV4-34 antibodies. (A) Antibodies using IGHV4-34 from normal donors. The germ-line IGHV-
34*01 amino acid sequence is shown at the top. In red are the residues of the hydrophobic patch that cause binding to self-antigens on the surface of B cells
and erythrocytes, notably I/i carbohydrates, with the AVY sequence boxed. In blue and boxed is the germ-line NHS N-glycosylation sequon in CDR2. Sequons
flanking residues that may modulate glycosylation efficiency analogous to Hy10 are also shown in bold. Aligned beneath are the corresponding sequences of
specific antibodies (switched IgG antibodies are italicized) elicited by immunization with a foreign antigen, revealed by an IGHV-34*01 Blastn search of the
NCBI nonredundant nucleotide database and analyzed using IMGT/V-QUEST. Identity to germ line is denoted by a dash, and substituted residues in CDR3 are
in dark red. The percentage of switched antibodies with mutations that inactivate the hydrophobic patch AVY sequence or the core NHS glycosylation
sequon, or both, is shown below for the switched antibodies of known specificity and in massively parallel cDNA sequences from memory B cells. Antibody
specificities and GenBank accession numbers are as follows: anti-RhD (16): FomA (X64153), Fom1 (X64152), Mad2 (X64159), R.D7C2 (A49385), Og31 (X64156),
Fog1 (X64150); anti-rotavirus (17): 7-94 (AF453121); anti-vaccinia (18): 589 (HQ378397), 520 (HQ378388), 166 (HQ378337), 31 (HQ378326), 225 (HQ378353),
274 (HQ378366); and anti-tetanus toxoid (19): 529E18 (JN111017). (B) Repertoire of mutated IGH cDNAs in IgD− CD27+ memory B cells in blood of normal
donors, analyzed by 454 massively parallel sequencing, showing the number of sequences for each IGHV gene and the percentage that have acquired an
N-glycosylation sequon. Excluded are IGHV genes with germ-line sequons (IGHV4-34, IGHV1-8, IGHV5-a) or with less than 20 reads.
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Fom1). The AVY sequence was also inactivated in IgG anti-
bodies against rotavirus and vaccinia. Overall, the AVY motif
was mutated in 5 of the 10 IGHV4-34 IgG antibodies, consistent
with earlier observations that this sequence is mutated more
frequently than would be expected by chance in switched B cells
of unknown specificity in surgically resected tonsils (12). To ex-
tend this analysis to normal memory B cells, we analyzed a total
of 78,074 VDJH sequences obtained by massively parallel se-
quencing of cDNA from sorted peripheral blood memory B cells
from 13 normal donors (21, 22). Nonsynonymous AVY sub-
stitutions occurred in 43% of the 3,030 IGHV4-34 memory B-cell
sequences (Fig. 1A).
N-Linked Glycosylation Sequons in Human Antibody V Regions.
IGHV4-34*01 is also unique among the family of IGHV4 ele-
ments because it has acquired during germ-line evolution an
Asn–X–Ser/Thr sequon promoting N-linked glycosylation of
CDR2 (Fig. 1A). Attachment of bulky oligosaccharides to CDR2
can interfere with binding to antigen (23), and a fraction of
immune IgG appears to be hemiglycosylated on one of the two
antigen-binding sites, preventing formation of multivalent im-
mune complexes (24). Among the foreign antigen-elicited anti-
bodies or memory B-cell cDNA IGHV4-34*01 sequences with an
inactivated AVY motif, 40% and 47%, respectively, had also
somatically inactivated the CDR2 glycosylation sequon (Fig. 1A).
We speculate that inactivation of the sequon could increase ac-
cessibility of their binding sites to the eliciting foreign antigens,
although this possibility will need to be tested experimentally in
future biophysical studies.
Almost all other germ-line human VH elements do not contain
an Asn–X–Ser/Thr sequon, although sequons can be generated
by somatic hypermutation (25, 26). In deep-sequenced cDNA
from human CD27+ IgD− memory B cells, N-glycosylation
sequons had been acquired by somatic mutation in 20–35% of
sequences using IGHV4-61, IGHV4-39, and IGHV4-59 but in
only 2–4% of those using IGHV3-23, IGHV6-1, IGHV3-7,
IGHV2-5, IGHV3-48, IGHV1-18, and IGHV3-15 (Fig. 1B). The
low frequency in IGHV3-23, IGHV3-48, and IGHV3-15 is nota-
ble because these contain hypermutation hotspots in CDR2
enabling the germ-line sequence to be converted into a glyco-
sylation sequon in the majority of follicular lymphomas using
these V elements (26). These results are consistent with in-
dependent estimates that 20% of normal human antibodies
carry N-linked glycans in their V domain (23, 24, 26–28).
Activation of Anergic B Cells to Form Germinal Centers in Mice. The
results above are consistent with the possibility that antibodies
can be selected in GCs to mutate away from self-reactivity. This
is the simplest explanation for frequent inactivation of AVY
sequences in switched IGHV4-34 antibodies, and has been
inferred previously (12). However, frequent inactivation of the
AVY motif could also result from a mutation hotspot or selec-
tion for better binding to foreign antigens (29), and these al-
ternative explanations cannot be excluded because the selecting
foreign and self-epitopes are heterogeneous and not well-defined
biophysically. To resolve this question experimentally, we ana-
lyzed anergic IgD+ IgMlow B cells expressing an antibody, Hy10,
recognizing a highly characterized epitope on hen egg lysozyme
(HEL) (30–32) under conditions where the same epitope was
displayed on foreign and self-antigens, or only on foreign an-
tigen as a control.
B cells expressing the Hy10 antibody were obtained from
MD4:ML5 double-transgenic mice making HEL protein as a
circulating self-protein at concentrations of ∼10−9 M. These
concentrations are higher than the KD of the Hy10 antibody, so
that >50% of BCR occupancy by circulating self-HEL protein
induced an IgD+ IgMlow anergic state (5, 33). As controls, IgD+
IgMhi naïve B cells unexposed to self-HEL were obtained from
MD4 single-transgenic mice. HEL-specific B cells (105) were
injected into nontransgenic mice, diluting them to a frequency
<0.01% of the recipient repertoire. The recipients were immu-
nized with HEL or a lower-affinity variant with two mutations in
antibody contact residues, HEL2X, coupled to the surface of sheep
red blood cells (SRBCs) to enable the anergic or naïve B cells to
bind the foreign immunogen and collaborate with SRBC-specific
T-follicular helper (TFH) cells required for GC formation. Flow
cytometric and immunofluorescence analysis 5–6 d later yielded
the surprising result that anergic cells usually produced more GC
progeny than naïve counterparts (Fig. 2 A–C). This was opposite
the decreased accumulation of plasmablasts from anergic B cells
previously observed during extrafollicular reactions driven by na-
ïve helper T cells that did not support GC differentiation (34–36)
or induced with SRBC-primed T cells in irradiated recipients (33).
Enhanced GC differentiation was also exhibited by the cor-
responding subset of IgD+ IgMlow B cells in the normal pre-
immune repertoire. Mature CD23+ B cells with the lowest and
highest quartiles of cell-surface IgM were sorted from normal B6
mice (Fig. 2D) and injected into congenic B6.CD45.1 recipients
together with SRBCs. Six days later, most of the CD45.2+ donor
B cells were not stimulated by the SRBC immunogen and
persisted either as IgMlow or IgMhi naïve B cells (Fig. 2 D–F) and
at comparable frequencies (Fig. 2G, Left), indicating that their
difference in cell-surface IgM is a stable trait and not simply
a maturation marker. A subset of the transferred IgMlow or IgMhi
CD45.2+ B cells were stimulated to differentiate into Fashi GL7+
GC cells, in competition with the much more numerous host-
derived CD45.1+ GC cells. IgMlow B cells nevertheless formed
twice as many GC cells as IgMhi B cells (Fig. 2G). The bias toward
GC differentiation in self-reactive B cells may result from de-
creased BCR signaling to NF-κB and consequent poor induction
of Ebi2 and Irf4 in anergic B cells (37), because induction of these
genes favors plasma cell differentiation and disfavors GC differ-
entiation (38–40).
Mouse Hy10 Antibody Variants Selected by Self-Antigen. VH hyper-
mutation and selection in the GC-differentiated progeny of
anergic cells were studied by performing cell transfers as above
but with anergic IgD+ IgMlow B cells from SWHEL:ML5 double-
transgenic mice that express Hy10 with the VDJH exon integrated
into the normal Igh locus (41). HEL was coupled to the foreign
carrier and was also expressed as self-HEL in half the recipients,
so that the SWHEL B cells would encounter identical epitopes on
foreign and self-antigens and any selection could not be attrib-
uted to conventional affinity maturation to the foreign antigen.
Analogous to the repeated immunizations with RhD+ eryth-
rocytes used to raise the human antibodies analyzed above, the
mice were boosted with repeated injections of HEL-coupled
erythrocytes on days 10, 18, and 24 (Fig. 3A). The last two
boosters were with HEL coupled to serologically non–cross-
reactive horse red blood cells (HRBCs) to minimize immunogen
clearance by SRBC-binding antibodies that develop by 14 d, and
to parallel the stimulation of broadly neutralizing antibodies to
conserved influenza hemagglutinin stalk epitopes by serologically
disparate virus strains (42). Anergic SWHEL B cells formed large
numbers of GC progeny on day 15 in immunized nontransgenic
recipients, where the GC progeny were free to accumulate without
ongoing binding of self-HEL (Fig. 3A). In HEL-transgenic recip-
ients, where the GC B cells concurrently encountered both self-
HEL and foreign HEL-SRBCs, accumulation of GC progeny was
greatly diminished during the early phase of the GC reaction on
day 15. This was consistent with previous evidence that binding
soluble or self-HEL triggers BCR down-regulation, migration to
the base of the GC dark zone, and apoptosis of GC cells (43, 44).
By contrast, self-HEL did not inhibit GC accumulation later in
the response.
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VDJH exon sequencing of single SWHEL GC cells early and late
in the response revealed that they accumulated as many VDJH
mutations per cell when exposed to self-HEL in the GCs as in
the controls (Fig. 3A), but recurring CDR2 amino acid sub-
stitutions became prevalent only when self-HEL was present
(Fig. 3B). By day 15, 42% of Hy10-expressing GC cells had ac-
quired a Ser52Asn substitution, and 40% of these had also ac-
quired a flanking Val51Ile mutation. By day 32, 93% had
acquired S52N and 95% of these paired S52N with flanking
V51I, S56R, or various S54 substitutions. In the absence of self-
HEL exposure during the GC reaction only 1–2% of GC cells
carried S52N and none paired S52N with V51I or S56R, dem-
onstrating that the CDR2 mutations were selected in response to
self-antigen and not by the foreign antigen on its own.
The recurrently substituted residues S52, S54, and S56 each
contact HEL, with S52 located at the center of the contact sur-
face, whereas V51 is immediately beneath (Fig. 4A). The fact
that many B cells on day 15 had only acquired S52N (Fig. 3B)
implied it was selected first, followed by the flanking CDR2
mutations. This was confirmed within individual recipients by
reconstructing mutation genealogies using rare (nonhotspot)
synonymous mutations as clonal markers (Fig. 4B). Hy10 IgG1
antibodies with the recurrent CDR2 mutations were expressed
and tested for binding the foreign immunogen HEL-SRBCs by
flow cytometry. At any fixed IgG1 concentration, ∼75% less
S52N antibody bound than wild-type Hy10, demonstrating that
this single mutation decreased either the affinity or avidity of
binding to the foreign immunogen (Fig. 4C). Pairing S52N with
V51I partly restored binding (Fig. 4C). Binding of wild-type
Hy10 to HEL-SRBCs was blocked by free HEL monomer at the
concentration that circulates in ML5 mice (5), whereas much
higher [HEL] monomer was required to block binding of the
mutated antibodies to the foreign antigen (Fig. 4D).
N-Linked Glycosylation of the Antigen-Binding Sites in Mutated Hy10.
The primary S52N mutation created a potential N-glycosylation
sequon within CDR2, N52–Y53–S54. SDS/PAGE confirmed that
S52N resulted in a second N-linked carbohydrate on 72% of H
chains (Fig. 4E), in addition to the expected glycan in the IgG1 C
region. Pairing S52N with S56R or V51I decreased the fraction
of V-region glycosylated H chains to 43% and 12%, respectively.
Substitution of flanking residues thus modulates the efficiency
of carbohydrate attachment to N–X–S/T sequons in antibody
V regions, consistent with observations in other proteins (45). V51I
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Fig. 2. IgMlow anergic B cells paradoxically make more GC progeny. (A–C) CD45.1-marked HEL-specific B cells (105) that were anergic (An) or naïve (Na) were
injected into normal C57BL/6 recipient mice together with 108 HEL-SRBCs or HEL2X-SRBCs. (A) Representative flow cytometric analysis of recipient spleen cells
5 d after immunization with HEL2X-SRBCs, gating on Fas+ CD38− GC B cells to enumerate percentage CD45.1+ donor-derived (Upper) or gating on CD45.1+
donor B cells (Lower) and measuring the percentage differentiated into B220low plasma cells with high intracellular HEL-binding antibody or into GC cells. (B)
Arithmetic means and data from individual recipients immunized with HEL2X-SRBCs (exp 1–4) or HEL-SRBCs (exp 5 and 6). Statistical analysis was by t test:
**P ≤ 0.01, ***P ≤ 0.001; n.s., not significant. (C) Representative immunofluorescence staining of a spleen cryosection from the recipient of anergic cells on
day 5 after immunization with HEL2X-SRBCs, locating most HEL-binding progeny (red) in GCs. (D–G) Mature CD23+ B cells from C57BL/6 mice were stained
with F(ab′) anti-IgM, and cells in the lowest (IgMlo; red histograms) or highest (IgMhi; blue histograms) quartile of cell-surface IgM were sorted and injected
into B6.SJL-CD45.2 congenic recipients, and the recipients were immunized with SRBCs. (D) Distribution of surface IgM on the sorted populations compared
with unsorted CD23+ B cells (gray-filled histogram) on day 0 (Upper) and compared with CD45.1+ recipient B220+ B cells 6 d after transfer (Lower). (E and F)
Surface IgM mean fluorescence intensity (MFI) on the sorted populations from separate donors at the time of transfer (E) and in separate recipients after 6 d
(F). (G) Frequency of CD45.2+ donor-derived cells among B220+ Fas− GL7− B cells (Left) or among B220+ Fas+ GL7+ GC cells (Center) in individual recipients,
and the total number of donor-derived GC cells (Right). Statistical analysis was done as above.
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or S56R were acquired by 42% of the S52N-bearing cells on day
32, and another 54% acquired an S54 substitution eliminating
the sequon itself (Fig. 3B), so that 95% of the B cells that had
initially acquired glycosylation of their antigen-binding sites had
cleared the majority of sites with a second CDR2 mutation.
S52 lies at the center of the buried surface between Hy10 and
HEL (30), and modeling studies predict a bulky carbohydrate
here would preclude antigen binding (Fig. 4F). Consistent with
that prediction, biosensor measurement of binding to and dis-
sociation from immobilized IgG of varying concentrations of
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WT3-8 Ch4-14 WT2-19 Ch3-1 N F
WT3-7 Ch4-2 WT2-2 Ch3-10 N I
WT3-6 Ch4-3 WT2-21 Ch3-11 N I
WT3-4 Ch4-4 WT2-22 Ch3-12 N I
WT3-3 N Ch4-8 WT2-23 Ch3-13 N I
WT3-27 Ch4-9 WT2-24 Ch3-14 N I
WT3-26 WT2-3 Ch3-15 N F
WT3-25 D WT2-4 Ch3-18 N F
WT3-24 WT2-6 Ch3-19 N I
WT3-23 WT2-8 Ch3-2 N F
WT3-22 WT2-9 Ch3-20 N I
WT3-21 WT3-1 Ch3-21 N F
WT3-20 WT3-10 Ch3-23 N I
WT3-2 WT3-11 F Ch3-24 N I
WT3-19 WT3-12 Ch3-3 N I
WT3-18 WT3-14 Ch3-4 N I
WT3-17 WT3-15 A F Ch3-5 N F
WT3-16 C N WT3-16 Ch3-7 N I
WT3-15 WT3-18 Ch3-8 N F
WT3-14 WT3-19 Ch4-16 N G
WT3-13 WT3-2 Ch4-2 N I
WT3-12 WT3-21 Ch4-5 N G
WT3-11 WT3-22 Ch4-7 S N I N
WT3-10 WT3-23 Ch1-14 N N G
WT3-1 WT3-3 Ch1-17 N N G
WT2-9 WT3-4 F Ch1-18 N N G
WT2-8 WT3-8 Ch1-21 N N G
WT2-7 WT1-5 A Ch3-17 N I G
WT2-6 S WT1-4 G C Ch4-18 N H G
WT2-5 WT2-7 G Ch4-9 N H G
WT2-4 WT1-11 I Ch1-19 N N
WT2-3 WT1-9 N Ch2-2 N I N
WT2-21 N WT2-10 N Ch2-21 N H I N
WT2-20 WT2-20 R S N Ch4-15 N I N
WT2-2 T WT3-20 H N Ch4-17 N H I N
WT2-19 WT1-12 T Ch4-21 N I N
WT2-18 WT3-24 T Ch4-23 N I N
WT2-17 WT3-5 T Ch1-1 N R
WT2-16 WT3-6 T Ch1-11 N R
WT2-15 WT3-7 T Ch1-13 N T R
WT2-12 A N WT3-9 Ch1-2 N R
WT2-11 Ch1-20 N R
WT2-10 Ch1-22 N R F
WT2-1 Ch1-5 N R
WT1-9  Ch1-6 N R
WT1-8  S T Ch1-8 N R
WT1-7  N D Ch2-11 N R
WT1-5  Ch2-14 N R
WT1-4  Ch2-16 N R
WT1-3  Ch2-18 N R
WT1-24 Ch2-20 N R
WT1-23 Ch2-23 N R
WT1-22 Ch2-8 N R
WT1-20 Ch3-22 N R
WT1-2  Ch4-11 N G R
WT1-19 Ch4-14 N G R
WT1-18 Ch4-20 N D R R
WT1-17 Ch4-6 N R
WT1-15 D N Ch4-8 N V R
WT1-14 Ch3-16 N I T
50 52 555451 53 56 57 58 59 50 52 555451 53 56 57 58 59 50 52 555451 53 56 57 58 59 50 52 555451 53 56 57 58 59
Day 15 no self-HEL: Day 15 + self-HEL: Day 32 no self-HEL: Day 32 + self-HEL:
B
Fig. 3. Recurring VH CDR2 mutations selected by self-
antigen. (A) Anergic CD45.1-marked HEL-specific B cells
(105) from SWHEL x ML5 donor mice were transferred
into non-Tg (no self-HEL) or ML5 HEL-Tg (+self-HEL)
C57BL/6 recipients together with HEL-SRBCs, and recip-
ients were boosted on the indicated days with HEL-
SRBCs or HEL-HRBCs. The % CD45.1+ cells among B220+
Fas+ GL7+ GC B cells in individual recipients on day 15
or 32 is shown. Single CD45.1+ B220+ Fas+ GL7+ cells
were sorted into microtiter plates for Hy10 VDJH exon
sequencing, yielding the mean number of VDJH nucle-
otide substitutions in B cells from individual recipients
and the SD of this mean between recipients. (B) Amino
acid changes in CDR2 in single sorted B cells after 15 or
32 d in recipients with or without self-HEL. Cells from
different mice are denoted by the prefix Ch1–Ch4 for
the four HEL-transgenic mice on day 15 and day 32, and
WT1–4 for the four non-Tg mice at each time point.
From each of the mice analyzed, the individual cells are
numbered with a suffix from 1 to 25. The Hy10 se-
quence for CDR2 residues 50–59 is shown above. Sub-
stitutions in individual cells are shown, clustered by
sequence similarity. The different colors denote re-
curring combinations of CDR2 mutations, often found
in several independent recipient mice, as indicated by
the Ch1–Ch4 prefix.
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soluble HEL monomer revealed that the maximum amount
bound to immobilized S52N IgG was ∼30% of wild type (Fig.
4G). For the sites that could bind, HEL dissociated 70 times
faster from S52N (kd 3 × 10
−3 s−1) than from wild-type Hy10
(kd 2 × 10
−5 s−1), reducing the overall KD from ∼1 × 10−10 M for
the wild-type binding site to 5 × 10−9 M for S52N (differences
between on-rates were minor for all of the analyzed mutants).
Pairing S52N with S56R or V51I preserved the lower affinity
(KD 6–9 × 10
−9 M, kd 2–3 × 10
−3 s−1) but increased the sites
available to bind, consistent with only a minority of VH regions
occupied by glycan. When single-chain variable fragments (scFvs)
were expressed in bacteria, where N-linked glycosylation cannot
occur, biosensor analysis confirmed that S52N did not result in any
difference in binding site availability but lowered affinity 100-fold,
whereas pairing S52N with V51I or S56R had little additional
effect on either measure (Table 1).
Discussion
Evolutionary selection for germ-line V, D, and J elements that
have a propensity to bind foreign antigens is likely to bring with it
propensity to bind self-antigens (46), as illustrated by the AVY
hydrophobic patch in IGHV4-34 promoting binding to foreign
RhD on allogeneic erythrocytes and to self-I/i on syngeneic
erythrocytes (13). The observations here provide two lines of
evidence that autoantibodies carried on anergic B cells can be
“redeemed” in response to foreign antigen by hypermutation and
selection in germinal centers to remove self-reactivity, instead of
being discarded by clonal deletion or receptor editing. First,
human antibodies using the IGHV4-34 germ-line gene uniformly
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Fig. 4. Mutation away from self-reactivity by modulating glycosylation, affinity, and avidity. (A) Location of mutated VH residues relative to the H-chain
contact surface with lysozyme in blue, from Protein Data Bank (PDB) ID code 3D9A (32). (B) Representative GC B-cell genealogies in individual recipients on
day 15 (Left; from mouse number Ch3) and day 32 (Right; from mouse number Ch1). Clonally related cells were identified by shared silent mutations in
nonhotspot VH nucleotides (italicized black). Recurrent nonsynonymous nucleotide and corresponding amino acid substitutions are colored; other mutations
are shown in black. Sequenced cells are numbered as in Fig. 2, and inferred precursors are indicated by dashed circles. (C and D) IgG1 antibodies with the wild-
type H-chain sequence (Hy10W) or the indicated CDR2 substitutions were expressed in CHO cells, and binding to HEL-SRBCs was detected by fluorescent anti-
IgG antibody and flow cytometry. MFI, geometric mean fluorescence intensity of IgG fluorescence on gated single erythrocytes. (C) Binding in the absence of
competing soluble HEL. (D) Percent inhibition of binding to HEL-SRBCs of 0.5 nM IgG in the presence of varying concentrations of HEL monomer in solution.
The dashed line denotes the mean concentration of self-HEL in the extracellular fluid of ML5 mice. (E) Hy10 IgG1 antibodies with the wild-type H-chain
sequence (Hy10W) or the indicated CDR2 substitutions were expressed in 293T cells, purified, and analyzed by SDS/PAGE under reducing conditions and
stained with Coomassie blue. Where indicated, N-linked carbohydrates were removed from the antibodies by treatment with PNGase F (+). The arrow
indicates mobility shift due to VH glycosylation. (F) Molecular model of V-region glycosylation, with carbohydrate (arrow) occupying the HEL antigen-binding
site. The model was generated using the structure of Hy10W bound to HEL (cartoon and transparent surface; PDB ID code 3D9A), with a single N-linked
branched NAG-FUC-NAG trisaccharide modeled onto Kabat position 52 of the variable heavy domain (colored sticks; glycan-derived from PDB ID code 3CA1).
(G) Biolayer interferometry measurements of binding of HEL antigen in solution to immobilized Hy10 IgG antibodies. Plotted is binding site occupancy
(% Hy10W maximum) versus Octet IU intensity units per antigen concentration (nm/M).
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bind self-antigens on erythrocytes, rendering B cells carrying
these antibodies anergic, but almost half the mutated IgG anti-
bodies or memory B-cell sequences using this V gene have ac-
quired somatic mutations in the AVY motif responsible for
binding to self-erythrocytes. Second, anergic mouse B cells
preferentially formed germinal centers in cell-transfer studies,
and those carrying the well-characterized Hy10 antibody to hen
egg lysozyme mutated away from self-reactivity by acquiring
CDR2 mutations when lysozyme was present as a self-antigen
and as a foreign antigen in the GC. N-linked glycosylation
of CDR2 in a fraction of the H chains appears to provide a
mechanism to modulate autoantibody avidity by occupying a
varying proportion of antibody-binding sites with glycan.
In the studies with Hy10, a single somatic mutation—S52N—
masked self-reactivity by causing the majority of binding sites to
become occupied with an N-linked glycan. S52N also diminished
self-reactivity by decreasing the affinity of the residual unglyco-
sylated sites by ∼100-fold. Acquisition of S52N was followed by
various flanking secondary mutations that partly or completely
prevented N-glycosylation, resulting in antibodies whose binding
sites were now available to bind antigen but with a greatly re-
duced affinity (KD 5–9 × 10
−9 M). The reduced affinity was less
than the circulating HEL concentration (10−9 M), so that only
a small proportion of sites would be occupied by self-HEL at any
one time, and the antibodies were now free to bind the multi-
valent HEL-SRBC antigen without competitive inhibition by the
circulating monomeric self-HEL. Despite identity of the HEL-
epitope on self- and foreign antigens, increasing the single-site
dissociation rate by ∼100-fold enabled the monomeric self-HEL
and polymeric array of foreign HEL on SRBCs to be discrimi-
nated by epitope valency and binding cooperativity. This paral-
lels the discrimination of sparsely arrayed self-glycans and densely
arrayed foreign glycans by mannose-binding protein (47) or by
a hypermutated antibody to HIV gp120 (48).
The high starting affinity of Hy10 for HEL has experimental
advantages and limitations. A chief advantage is that Hy10 af-
finity has already been optimized by repeated immunization of
the mouse that yielded the Hy10 hybridoma, making it possible
here to study selection by self-antigen of affinity-lowering mutations
without concurrent selection by foreign antigen for affinity-
raising mutations. The lack of selection for affinity-raising muta-
tions presumably explains the absence of recurring mutations in
SWHEL B cells responding to HEL-SRBCs alone in nontransgenic
control recipients. Because S52N became frequent only in B cells
responding to HEL-SRBCs in the presence of self-HEL, its ac-
quisition was driven by the presence of self-HEL and was not the
result of a mutation hotspot or an indirect effect of selection for
increased affinity for the foreign antigen. These three alternative
explanations are difficult to disentangle in the case of recurrent
mutations found in VH4-34+ antibodies or in other physiological
antibody responses.
A limitation of the high affinity is that it could be argued that the
findings with Hy10 may not be generalizable to physiological anti-
body responses, because most preimmune antibodies would have
much lower affinity for self-antigens and their binding sites would
not be as highly occupied by self-antigen. However, comparable
competitive inhibition would be expected when antibodies in the
preimmune repertoire start out with low affinity (e.g., KD 10
−6 M)
for serum glycoproteins such as IgG, because IgG is present at
concentrations of greater than 10−6 M. Likewise, the concentration
of I/i glycoproteins in serum and on self-erythrocytes is likely to be
very high, and they compete for binding of unmutated VH4-34+
antibodies to RhD, vaccinia virus, or tetanus toxoid.
Selection in GCs for decreased antibody affinity and avidity is
surprising because antibody hypermutation in GCs has primarily
been considered to underpin increases in affinity (49), driven by
B-cell competition to capture and present antigen to TFH cells
(50). When an antibody recognizes self- and foreign epitopes
that differ in tertiary structure, such as VH4-34 antibody rec-
ognition of self-I/i versus foreign RhD or vaccinia, decreased
affinity for self could arise as a passive by-product of positive
selection for better structural fit and higher binding affinity
against the foreign epitope (29). This type of passive selection
against self-reactivity is nevertheless excluded in the Hy10 ex-
periments with HEL because (i) it is not observed in control
recipients where the GC B cells only encountered foreign HEL
and (ii) the mutations selected in the presence of self-HEL also
decrease binding to the foreign HEL measured either free in
solution or conjugated to SRBCs.
Although the findings here demonstrate acquisition of self/
non-self discrimination by antibody mutation away from self-
reactivity, future studies will need to investigate how lower af-
finity for self was selected. Positive selection by TFH cells could
actively select for lower-affinity binding because GC B cells
whose BCRs are mostly occupied by self-HEL or self-I/i carbo-
hydrates will have fewer binding sites available to capture HEL-
SRBCs or RhD antigens and present fewer peptides to TFH cells.
Progeny with mutated antibodies of lower affinity for self, and
consequently less self-occupancy, might paradoxically capture
more foreign antigen and receive more help rather than less.
This would ensure that secreted antibody binding to foreign
antigen is not outcompeted by self-antigen, nor rapidly cleared
from the circulation by binding self-antigens.
However, selection by TFH cells does not readily account for
self-antigen–driven acquisition of S52N in Hy10, because the
mutation blocked most antigen-binding sites with glycan to di-
minish sites available to take up foreign HEL-SRBCs. An active
negative effect of self-antigen itself (44) provides an alternative
explanation for the acquisition of S52N. In experiments where
HEL was injected at the height of a GC response by Hy10-
expressing B cells, it triggered the GC cells to concentrate in the
dark zone away from TFH cells and to down-regulate surface
BCRs within 2 h, followed by a wave of apoptosis after 4 h (43).
BCR engagement by foreign HEL-SRBC fragments presented in
the GC light zone may also trigger migration back to the dark
zone (50), but once in the dark zone the GC cells would get relief
from this BCR signal to regain surface BCRs and the capacity to
migrate back to the light zone. By contrast, self-antigen that is
circulating or on the membrane of all cells would continue to
stimulate the BCRs once the cells have moved to the dark zone,
signaling them to stay removed from TFH cells and down-regulating
their surface BCRs to deprive the cells of a tonic PI3-kinase survival
Table 1. Biolayer interferometry measurements of binding of
HEL antigen in solution to immobilized Hy10 antibodies
produced as glycosylated IgG in mammalian cells and
aglycosylated scFv in bacteria
Antibody KD, M ka, M
−1 s−1 kd, s
−1
Occupancy,
%
Hy10 (IgG)
WT 9 × 10−11 2.60 × 10−5 2.30 × 10−5 100
S52N 5 × 10−9 5.46 × 10−5 2.80 × 10−3 27
S52N/
S56R
6 × 10−9 4.34 × 10−5 2.81 × 10−3 53
V51I/
S52N
9 × 10−9 2.41 × 10−5 2.17 × 10−3 76
Hy10 (scFv)
WT <1 × 10−10 1.71 × 10−5 <10−5 100
S52N 2 × 10−9 4.63 × 10−5 7.11 × 10−4 109
S52N/
S56R
5 × 10−9 2.31 × 10−5 1.12 × 10−3 99
V51I/
S52N
4 × 10−9 2.65 × 10−5 9.88 × 10−4 96
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signal (51). Masking the antigen-binding sites with glycan may
relieve this continuous BCR signal from self-antigen. Recurrent
selection for acquired V-region N-glycosylation sequons in follicular
lymphomas (26) might also be driven by masking of self-reactivity to
increase the pool of surface BCRs delivering PI3-kinase survival
signals. Glycosylated BCRs may also be recognized by lectins
on follicular dendritic cells or macrophages in the germinal
center to deliver a survival advantage (26).
A need for some preimmune antibodies to mutate away from
self-reactivity provides an alternative explanation for the phe-
nomenon of repertoire shift during the maturation of antibody
responses, when certain antibody specificities that ultimately
dominate responses to haptens (52–57) or RhD alloantigens
(16, 20) or bind conserved neutralizing epitopes of viruses (58–62)
are minimally represented in the primary wave of plasma cells but
gradually emerge after repetitive stimulation by foreign antigen.
Inherited defects that prevent hypermutation away from self-re-
activity by antimicrobial antibodies may explain the surprising
prevalence of autoantibodies in human AICDA deficiency, where
GCs are formed but hypermutation is crippled (63). Structural
constraints that make it difficult for mutations to remove self-
binding without also losing binding to the eliciting foreign an-
tigen, as has been shown for VH4-34 antibodies against RhD (13)
and for the 2F5 broadly neutralizing antibody against HIV (61),
may explain the difficulty eliciting high titers of certain broadly
neutralizing antibodies against viruses (60–62).
Materials and Methods
Human Memory B-Cell Repertoire Analysis by Massively Parallel Sequencing.
CD19+ CD27+ IgD− peripheral blood mononuclear cells were isolated from
13 healthy donors (18–86 y) after obtaining written consent as approved by
the Guy’s Hospital Research ethics committee, London. cDNA was synthe-
sized, and Ig genes were PCR-amplified by a seminested, isotype-specific
reaction and sequenced on the 454 GS FLX Titanium Sequencer as previously
described (21, 22). The accuracy of the method as a whole was determined
using analysis of results from a control Ig gene and was less than one error
per 300 bp, or one per 1,300 bp if indels (a known issue with the sequencing
platform) were discounted. Sequences were assigned an isotype and aber-
rant PCR products were removed after the data was checked for quality
based on presence and orientation of sequence motifs, together with min-
imum- and maximum-size thresholds based on plausible limits determined
by germ-line Ig organization as previously described (21, 22). Sequences that
passed these initial quality control criteria but whose reads were too short to
span the CDR3 region were excluded as uninformative. For the remaining
sequences, the IGHV, IGHD, and IGHJ gene usage and amino acid sequence of
each region of the variable region were determined using IMGT/V-QUEST (64)
allowing for indels. This provides a second round of quality control, with only
sequences that generated a V-QUEST output and spanned the CDR3 region
being analyzed further. The amino acid sequence of the VDJ region was de-
fined on the basis of the V-QUEST output, and sequon motifs were identified
using regular expression searches for N[̂ P][ST] (N followed by any amino acid
other than a P, followed by an S or T). Data were combined and subsequent
analyses were performed in Excel (Microsoft). A total of 78,074 sequences
were obtained frommemory B cells. Of these, 3,030 were IGHV4-34 genes that
had an IGHV region greater than 74 bp, and 14,475 were mutated sequences
from CD27+ IgD− memory cells using genes other than IGHV4-34, IGHV5a, or
IGHV1-8 (the genes that have a sequon in germ-line configuration).
Adoptive Transfers. Recipients were C57BL/6 nontransgenic or ML5 HEL-
transgenic mice. Donors were MD4, MM4, or SWHEL C57BL/6.SJL-Ptprc
a
(CD45.1) congenic mice. Mice were bred and housed under specific patho-
gen-free conditions at the Australian National University (ANU), and all
procedures were approved by the ANU Animal Ethics and Experimentation
Committee. Spleen cells containing 105 HEL-binding B cells were i.v. injected
together with 2 × 108 SRBCs conjugated to HEL or HEL2X and boosted by i.v.
injection of 2 × 108 HEL-SRBCs or HEL-HRBCs, and recipient spleen cells were
analyzed 5–32 d later by flow cytometry, single-cell sorting, H-chain se-
quencing, and cryosection staining as described previously (65, 66). For
responses by nontransgenic B cells, B6 spleen cells were stained with anti-
body to CD23 (BioLegend) and Alexa647-conjugated F(ab′) fragments of
goat anti-mouse IgM antibody (Jackson ImmunoResearch) and sorted into
IgMlow and IgMhi quartiles. Preliminary studies established that this combi-
nation of antibodies did not alter the survival of stained B cells after in-
jection into congenic B6.CD45.1 recipients. Sorted B cells (1.5 × 106) were
injected with SRBCs (2 × 108) into the lateral tail vein of individual B6.CD45.1
recipients, and 6 d later spleen cell suspensions were analyzed by flow
cytometry as above.
Expression, Purification, and Deglycosylation of Hy10 IgG Variants. Plasmid
DNA (pcDNA3; Invitrogen) containing the unmodified Hy10 light-chain gene
or wild-type, S52N, V51I/S52N, or S52N/S56R versions of the Hy10 IgG1 heavy-
chain gene were cotransfected at a 4:1 light-to-heavy ratio into CHO or
HEK293F cells (Invitrogen). Transfections were performed using the Lip-
ofectamine 2000 reagent (Invitrogen) per the manufacturer’s instructions,
and recombinant antibodies were purified from culture supernatants at day
7 after transfection using Protein G Sepharose 4 Fast Flow (GE Healthcare
Life Sciences). Eluted IgG samples were dialyzed into PBS using SnakeSkin
dialysis tubing with a 3.5-kDa molecular weight cutoff (Thermo Scientific).
Ten micrograms of IgG was treated with PNGase F per the manufacturer’s
instructions (New England Biolabs) and first incubated 10 min at 94 °C in the
presence of denaturing buffer, followed by addition of PNGase F in Nonidet
P-40 and G7 (50 mM sodium phosphate pH 7.5) buffers overnight at 37 °C.
This process was replicated without PNGase F as a negative control. Treated
samples were analyzed by SDS/PAGE on precast 4–12% bis-Tris gels (NuPAGE;
Invitrogen), visualized with InstantBlue protein stain (Expedeon), and subjected
to densitometry analyses.
Affinity Measurements. For HEL-SRBC binding studies, culture supernatants
were analyzed by ELISA to determine IgG concentration, diluted to 0.5 nM
IgG in PBS buffer with varying [HEL], incubated for 2 h before addition to HEL-
SRBCs, washed, developedwith fluorescent anti-IgG antibodies, and analyzed
by flow cytometry as described previously (65). For biolayer interferometry
measurements (ForteBio), purified samples of wild-type or mutant Hy10
were biotinylated at a 5:1 molar ratio using EZ-Link NHS-PEO4-Biotinylation
reagent followed by desalting on a Zeba Spin column (Thermo Scientific).
Streptavidin biosensors were preblocked with 1% BSA in PBS for 1 h and
incubated with biotinylated antibody. The coupling of antibody to sensors
was quantified by biolayer interferometry. Measurements were conducted
using hen egg lysozyme (Sigma-Aldrich) diluted in PBS buffer.
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